SEARCH

SEARCH BY CITATION

References

  • Addington J., McCleary L. and Munroe-Blum H. (1998) Relationship between cognitive and social dysfunction in schizophrenia. Schizophr. Res. 34, 5966.
  • Albus M., Hubmann W., Ehrenberg C., Forcht U., Mohr F., Sobizack N., Wahlheim C. and Hecht S. (1996) Neuropsychological impairment in first-episode and chronic schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci. 246, 249255.
  • Angrist B. and Sudilovsky A. (1978) Central nervous system stimulants: historical aspects and clinical effects, in Handbook of psychopharmacology (IversenL. L., ed.), Vol. 11, pp. 99165. Plenum Press, New York.
  • Asarnow R. F. (1999) Neurocognitive impairments in schizophrenia: a piece of the epigenetic puzzle. Eur. Child Adolesc. Psychiatry 8(Suppl. 1), I5I8.
  • Bartos M., Vida I. and Jonas P. (2007) Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nat. Rev. Neurosci. 8, 4556.
  • Baskys A., Bayazitov I., Fang L., Blaabjerg M., Poulsen F. R. and Zimmer J. (2005) Group I metabotropic glutamate receptors reduce excitotoxic injury and may facilitate neurogenesis. Neuropharmacology 49(Suppl. 1), 146156.
  • Benarroch E. E. (2008) Metabotropic glutamate receptors: synaptic modulators and therapeutic targets for neurologic disease. Neurology 70, 964968.
  • Ben-Shachar D. (2002) Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J. Neurochem. 83, 12411251.
  • Bolonna A. A., Kerwin R. W., Munro J., Arranz M. J. and Makoff A. J. (2001) Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia. Schizophr. Res. 47, 99103.
  • Braithwaite S. P., Adkisson M., Leung J., Nava A., Masterson B., Urfer R., Oksenberg D. and Nikolich K. (2006) Regulation of NMDA receptor trafficking and function by striatal-enriched tyrosine phosphatase (STEP). Eur. J. Neurosci. 23, 28472856.
  • Bray N. J., Williams N. M., Bowen T. et al. (2000) No evidence for association between a non-synonymous polymorphism in the gene encoding human metabotropic glutamate receptor 7 and schizophrenia. Psychiatr. Genet. 10, 8386.
  • Brody S. A., Conquet F. and Geyer M. A. (2003) Disruption of prepulse inhibition in mice lacking mGluR1. Eur. J. Neurosci. 18, 33613366.
  • Brody S. A., Conquet F. and Geyer M. A. (2004) Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology (Berl) 172, 187195.
  • Buchanan R. W., Conley R. R., Dickinson D., Ball M. P., Feldman S., Gold J. M. and McMahon R. P. (2008) Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am. J. Psychiatry 165, 8289.
  • Buonanno A. and Fischbach G. D. (2001) Neuregulin and ErbB receptor signaling pathways in the nervous system. Curr. Opin. Neurobiol. 11, 287296.
  • Carlsson M. L., Carlsson A. and Nilsson M. (2004) Schizophrenia: from dopamine to glutamate and back. Curr. Med. Chem. 11, 267277.
  • Cartmell J. and Schoepp D. D. (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. J. Neurochem. 75, 889907.
  • Conklin H. M., Curtis C. E., Calkins M. E. and Iacono W. G. (2005) Working memory functioning in schizophrenia patients and their first-degree relatives: cognitive functioning shedding light on etiology. Neuropsychologia 43, 930942.
  • Conn P. J., Lindsley C. W. and Jones C. K. (2009) Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol. Sci. 30, 2531.
  • Corti C., Battaglia G., Molinaro G., Riozzi B., Pittaluga A., Corsi M., Mugnaini M., Nicoletti F. and Bruno V. (2007) The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J. Neurosci. 27, 82978308.
  • Coyle J. T., Tsai G. and Goff D. (2003) Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann. N Y Acad. Sci. 1003, 318327.
  • Crow T. J. (1998) Schizophrenia as a transcallosal misconnection syndrome. Schizophr. Res. 30, 111114.
  • Cryan J. F., Kelly P. H., Neijt H. C., Sansig G., Flor P. J. and Van Der Putten H. (2003) Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur. J. Neurosci. 17, 24092417.
  • Cull-Candy S. G. and Leszkiewicz D. N. (2004) Role of distinct NMDA receptor subtypes at central synapses. Sci. STKE 2004, re16.
  • David H. N. and Abraini J. H. (2002) Group III metabotropic glutamate receptors and D1-like and D2-like dopamine receptors interact in the rat nucleus accumbens to influence locomotor activity. Eur. J. Neurosci. 15, 869875.
  • Dickinson D. and Coursey R. D. (2002) Independence and overlap among neurocognitive correlates of community functioning in schizophrenia. Schizophr. Res. 56, 161170.
  • Durand D., Pampillo M., Caruso C. and Lasaga M. (2008) Role of metabotropic glutamate receptors in the control of neuroendocrine function. Neuropharmacology 55, 577583.
  • Eastvold A. D., Heaton R. K. and Cadenhead K. S. (2007) Neurocognitive deficits in the (putative) prodrome and first episode of psychosis. Schizophr. Res. 93, 266277.
  • Van Elst L. T., Valerius G., Buchert M., Thiel T., Rusch N., Bubl E., Hennig J., Ebert D. and Olbrich H. M. (2005) Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol. Psychiatry 58, 724730.
  • Erlenmeyer-Kimling L. (2000) Neurobehavioral deficits in offspring of schizophrenic parents: liability indicators and predictors of illness. Am. J. Med. Genet. 97, 6571.
  • Fallin M. D., Lasseter V. K., Avramopoulos D. et al. (2005) Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am. J. Hum. Genet. 77, 918936.
  • Fatemi S. H., Cuadra A. E., El-Fakahany E. E., Sidwell R. W. and Thuras P. (2000) Prenatal viral infection causes alterations in nNOS expression in developing mouse brains. Neuroreport 11, 14931496.
  • Ford J. M. and Mathalon D. H. (2008) Neural synchrony in schizophrenia. Schizophr. Bull. 34, 904906.
  • Ford J. M., Roach B. J., Faustman W. O. and Mathalon D. H. (2007) Synch before you speak: auditory hallucinations in schizophrenia. Am. J. Psychiatry 164, 458466.
  • Frankle W. G., Lerma J. and Laruelle M. (2003) The synaptic hypothesis of schizophrenia. Neuron 39, 205216.
  • Friston K. J. (1998) The disconnection hypothesis. Schizophr. Res. 30, 115125.
  • Gaspar P. A., Bosman C., Ruiz S. and Aboitiz F. (2009) The aberrant connectivity Hypothesis in schizophrenia, in From Attention to Goal-Directed Behavior: Neurodynamical, Methodological and Clinical Trends (CosmelliD. ed.), Vol. XVIII, pp. 301323. Springer, Berlin.
  • Gasparini F., Bilbe G., Gomez-Mancilla B. and Spooren W. (2008) mGluR5 antagonists: discovery, characterization and drug development. Curr. Opin. Drug Discov. Devel. 11, 655665.
  • Gerber D. J., Hall D., Miyakawa T., Demars S., Gogos J. A., Karayiorgou M. and Tonegawa S. (2003) Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc. Natl Acad. Sci. USA 100, 89938998.
  • Goldman-Rakic P. S. (1994) Working memory dysfunction in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 6, 348357.
  • Gozzi A., Large C. H., Schwarz A., Bertani S., Crestan V. and Bifone A. (2008) Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology 33, 16901703.
  • Gray L., Van Den Buuse M., Scarr E., Dean B. and Hannan A. J. (2009) Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation. Int. J. Neuropsychopharmacol. 12, 4560.
  • Green M. F. (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153, 321330.
  • Green M. F. and Nuechterlein K. H. (1999) Should schizophrenia be treated as a neurocognitive disorder? Schizophr. Bull. 25, 309319.
  • Gupta D. S., McCullumsmith R. E., Beneyto M., Haroutunian V., Davis K. L. and Meador-Woodruff J. H. (2005) Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 57, 123131.
  • Hahn C. G., Wang H. Y., Cho D. S. et al. (2006) Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat. Med. 12, 824828.
  • Harrison P. J. (1999) The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122, 593624.
  • Harrison P. J. and Weinberger D. R. (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10, 4068; image 45.
  • Harrison P. J., Lyon L., Sartorius L. J., Burnet P. W. and Lane T. A. (2008) The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J. Psychopharmacol. 22, 308322.
  • Hoffman R. E. and McGlashan T. H. (1998) Reduced corticocortical connectivity can induce speech perception pathology and hallucinated ‘voices’. Schizophr. Res. 30, 137141.
  • Homayoun H., Stefani M. R., Adams B. W., Tamagan G. D. and Moghaddam B. (2004) Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 29, 12591269.
  • Hubl D., Koenig T., Strik W. et al. (2004) Pathways that make voices: white matter changes in auditory hallucinations. Arch. Gen. Psychiatry 61, 658668.
  • Huguelet P., Zanello A. and Nicastro R. (2000) A study of visual and auditory verbal working memory in schizophrenic patients compared to healthy subjects. Eur. Arch. Psychiatry Clin. Neurosci. 250, 7985.
  • Iversen S. D. and Iversen L. L. (2007) Dopamine: 50 years in perspective. Trends Neurosci. 30, 188193.
  • Javitt D. C. (1987) Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatry 9, 1235.
  • Kim J. S., Kornhuber H. H., Schmid-Burgk W. and Holzmuller B. (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20, 379382.
  • Kim C. H., Lee J., Lee J. Y. and Roche K. W. (2008) Metabotropic glutamate receptors: phosphorylation and receptor signaling. J. Neurosci. Res. 86, 110.
  • Kinney G. G., Burno M., Campbell U. C., Hernandez L. M., Rodriguez D., Bristow L. J. and Conn P. J. (2003) Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther. 306, 116123.
  • Kinney G. G., O’Brien J. A., Lemaire W. et al. (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther. 313, 199206.
  • Kinoshita Y., Suzuki T., Ikeda M., Kitajima T., Yamanouchi Y., Inada T., Yoneda H., Iwata N. and Ozaki N. (2005) No association with the calcineurin A gamma subunit gene (PPP3CC) haplotype to Japanese schizophrenia. J. Neural Transm. 112, 12551262.
  • Krystal J. H., Karper L. P., Seibyl J. P., Freeman G. K., Delaney R., Bremner J. D., Heninger G. R., Bowers M. B. Jr and Charney D. S. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199214.
  • Krystal J. H., Bennett A., Abi-Saab D., Belger A., Karper L. P., D’Souza D. C., Lipschitz D., Abi-Dargham A. and Charney D. S. (2000) Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol. Psychiatry 47, 137143.
  • Krystal J. H., Abi-Saab W., Perry E. et al. (2005) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 179, 303309.
  • Lahti A. C., Koffel B., LaPorte D. and Tamminga C. A. (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13, 919.
  • Lane H. Y., Liu Y. C., Huang C. L., Chang Y. C., Liau C. H., Perng C. H. and Tsai G. E. (2008) Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol. Psychiatry 63, 912.
  • Lang U. E., Puls I., Muller D. J., Strutz-Seebohm N. and Gallinat J. (2007) Molecular mechanisms of schizophrenia. Cell. Physiol. Biochem. 20, 687702.
  • Lau C. G. and Zukin R. S. (2007) NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat. Rev. Neurosci. 8, 413426.
  • Lavreysen H. and Dautzenberg F. M. (2008) Therapeutic potential of group III metabotropic glutamate receptors. Curr. Med. Chem. 15, 671684.
  • Levitt P., Ebert P., Mirnics K., Nimgaonkar V. L. and Lewis D. A. (2006) Making the case for a candidate vulnerability gene in schizophrenia: convergent evidence for regulator of G-protein signaling 4 (RGS4). Biol. Psychiatry 60, 534537.
  • Lewis D. A., Hashimoto T. and Volk D. W. (2005) Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6, 312324.
  • Linden A. M., Johnson B. G., Peters S. C. et al. (2002) Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor. Neuropharmacology 43, 251259.
  • Lisman J. E., Coyle J. T., Green R. W., Javitt D. C., Benes F. M., Heckers S. and Grace A. A. (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 31, 234242.
  • Liu Y. L., Fann C. S., Liu C. M. et al. (2007) More evidence supports the association of PPP3CC with schizophrenia. Mol. Psychiatry 12, 966974.
  • Lyon L., Kew J. N., Corti C., Harrison P. J. and Burnet P. W. (2008) Altered hippocampal expression of glutamate receptors and transporters in GRM2 and GRM3 knockout mice. Synapse 62, 842850.
  • Malhotra A. K., Adler C. M., Kennison S. D., Elman I., Pickar D. and Breier A. (1997) Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol. Psychiatry 42, 664668.
  • Masu M., Nakajima Y., Moriyoshi K., Ishii T., Akazawa C. and Nakanashi S. (1993) Molecular characterization of NMDA and metabotropic glutamate receptors. Ann. N Y Acad. Sci. 707, 153164.
  • Medoff D. R., Holcomb H. H., Lahti A. C. and Tamminga C. A. (2001) Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus 11, 543550.
  • Mei L. and Xiong W. C. (2008) Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 9, 437452.
  • Mirnics K., Middleton F. A., Marquez A., Lewis D. A. and Levitt P. (2000) Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28, 5367.
  • Miyakawa T., Leiter L. M., Gerber D. J., Gainetdinov R. R., Sotnikova T. D., Zeng H., Caron M. G. and Tonegawa S. (2003) Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc. Natl Acad. Sci. USA 100, 89878992.
  • Moghaddam B. (2004) Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 174, 3944.
  • Moghaddam B., Adams B., Verma A. and Daly D. (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17, 29212927.
  • Mohler H. (2007) Molecular regulation of cognitive functions and developmental plasticity: impact of GABAA receptors. J. Neurochem. 102, 112.
  • Ohtsuki T., Koga M., Ishiguro H. et al. (2008) A polymorphism of the metabotropic glutamate receptor mGluR7 (GRM7) gene is associated with schizophrenia. Schizophr. Res. 101, 916.
  • Olney J. W. and Farber N. B. (1995) NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13, 335345.
  • Palucha-Poniewiera A., Klodzinska A., Stachowicz K., Tokarski K., Hess G., Schann S., Frauli M., Neuville P. and Pilc A. (2008) Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. Neuropharmacology 55, 517524.
  • Park S., Puschel J., Sauter B. H., Rentsch M. and Hell D. (2002) Spatial selective attention and inhibition in schizophrenia patients during acute psychosis and at 4-month follow-up. Biol. Psychiatry 51, 498506.
  • Patil S. T., Zhang L., Martenyi F. et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 13, 11021107.
  • Paul S., Nairn A. C., Wang P. and Lombroso P. J. (2003) NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. Nat. Neurosci. 6, 3442.
  • Paz R. D., Tardito S., Atzori M. and Tseng K. Y. (2008) Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur. Neuropsychopharmacol. 18, 773786.
  • Pietraszek M., Gravius A., Schafer D., Weil T., Trifanova D. and Danysz W. (2005) mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology 49, 7385.
  • Pisani A., Gubellini P., Bonsi P., Conquet F., Picconi B., Centonze D., Bernardi G. and Calabresi P. (2001) Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 106, 579587.
  • Rowland L. M., Astur R. S., Jung R. E., Bustillo J. R., Lauriello J. and Yeo R. A. (2005) Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology 30, 633639.
  • Salter M. W. and Kalia L. V. (2004) Src kinases: a hub for NMDA receptor regulation. Nat. Rev. Neurosci. 5, 317328.
  • Scannevin R. H. and Huganir R. L. (2000) Postsynaptic organization and regulation of excitatory synapses. Nat. Rev. Neurosci. 1, 133141.
  • Seeman P. (2006) Targeting the dopamine D2 receptor in schizophrenia. Expert Opin. Ther. Targets 10, 515531.
  • Shergill S. S., Kanaan R. A., Chitnis X. A. et al. (2007) A diffusion tensor imaging study of fasciculi in schizophrenia. Am. J. Psychiatry 164, 467473.
  • Smialowska M., Wieronska J. M., Domin H. and Zieba B. (2007) The effect of intrahippocampal injection of group II and III metobotropic glutamate receptor agonists on anxiety; the role of neuropeptide Y. Neuropsychopharmacology 32, 12421250.
  • Snyder S. H., Banerjee S. P., Yamamura H. I. and Greenberg D. (1974) Drugs, neurotransmitters, and schizophrenia. Science 184, 12431253.
  • Spencer K. M., Nestor P. G., Niznikiewicz M. A., Salisbury D. F., Shenton M. E. and McCarley R. W. (2003) Abnormal neural synchrony in schizophrenia. J. Neurosci. 23, 74077411.
  • Stahl S. M. (2007) The genetics of schizophrenia converge upon the NMDA glutamate receptor. CNS Spectr. 12, 583588.
  • Stefansson H., Rujescu D., Cichon S. et al. (2008) Large recurrent microdeletions associated with schizophrenia. Nature 455, 232236.
  • Stephan K. E., Baldeweg T. and Friston K. J. (2006) Synaptic plasticity and dysconnection in schizophrenia. Biol. Psychiatry 59, 929939.
  • Stone J. M., Morrison P. D. and Pilowsky L. S. (2007) Glutamate and dopamine dysregulation in schizophrenia–a synthesis and selective review. J. Psychopharmacol. 21, 440452.
  • Takaki H., Kikuta R., Shibata H., Ninomiya H., Tashiro N. and Fukumaki Y. (2004) Positive associations of polymorphisms in the metabotropic glutamate receptor type 8 gene (GRM8) with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 128B, 614.
  • Tallon-Baudry C., Bertrand O., Peronnet F. and Pernier J. (1998) Induced gamma-band activity during the delay of a visual short-term memory task in humans. J. Neurosci. 18, 42444254.
  • Tallon-Baudry C., Bertrand O. and Fischer C. (2001) Oscillatory synchrony between human extrastriate areas during visual short-term memory maintenance. J. Neurosci. 21, RC177.
  • Tuominen H. J., Tiihonen J. and Wahlbeck K. (2005) Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 72, 225234.
  • Umbricht D., Koller R., Vollenweider F. X. and Schmid L. (2002) Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol. Psychiatry 51, 400406.
  • Vernon A. C., Croucher M. J. and Dexter D. T. (2008) Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson’s model. Neuroreport 19, 475478.
  • Walsh T., McClellan J. M., McCarthy S. E. et al. (2008) Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320, 539543.
  • Wang C., Kaufmann J. A., Sanchez-Ross M. G. and Johnson K. M. (2000) Mechanisms of N-methyl-D-aspartate-induced apoptosis in phencyclidine-treated cultured forebrain neurons. J. Pharmacol. Exp. Ther. 294, 287295.
  • Wang C., McInnis J., Ross-Sanchez M., Shinnick-Gallagher P., Wiley J. L. and Johnson K. M. (2001) Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107, 535550.
  • Whitfield-Gabrieli S., Thermenos H. W., Milanovic S. et al. (2009) Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc. Natl Acad. Sci. USA 106, 12791284.
  • Whitford T. J., Farrow T. F., Rennie C. J., Grieve S. M., Gomes L., Brennan J., Harris A. W. and Williams L. M. (2007) Longitudinal changes in neuroanatomy and neural activity in early schizophrenia. Neuroreport 18, 435439.
  • Womelsdorf T. and Fries P. (2006) Neuronal coherence during selective attentional processing and sensory-motor integration. J. Physiol. Paris 100, 182193.
  • Zeng H., Chattarji S., Barbarosie M., Rondi-Reig L., Philpot B. D., Miyakawa T., Bear M. F. and Tonegawa S. (2001) Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell 107, 617629.